Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | SLC26A6 | Q9BXS9 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4040410 | 0.93 | KIF11 (0.60) | KIF11SMN1; SMN2HPGD | |
| SCHEMBL5790991 | 0.88 | KIF11 (0.49) | KIF11SMN1; SMN2MAPTPOLBHPGD | |
| SCHEMBL5899066 | 0.87 | KIF11 (0.54) | KIF11SMN1; SMN2POLBHPGDSLC26A6 | |
| SCHEMBL3901568 | 0.85 | KIF11 (0.49) | KIF11SMN1; SMN2MAPTSLC26A6NPSR1 | |
| SCHEMBL3875862 | 0.81 | KIF11 (0.56) | KIF11SMN1; SMN2MAPTPOLBHPGD | |
| SCHEMBL5898996 | 0.81 | KIF11 (0.58) | KIF11SMN1; SMN2MAPTPOLBHPGD | |
| SCHEMBL5787757 | 0.81 | KIF11 (0.51) | KIF11SMN1; SMN2POLBHPGDSLC26A6 | |
| SCHEMBL6208538 | 0.79 | PDE4A (0.51) | KIF11SMN1; SMN2MAPTPOLBTP53 | |
| SCHEMBL5899045 | 0.79 | KIF11 (0.51) | KIF11SMN1; SMN2POLBHPGDSLC26A6 | |
| SCHEMBL3888693 | 0.77 | KIF11 (0.51) | KIF11SMN1; SMN2MAPTPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| EP-1601673-B1 | FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-06-10 | — | — | EP | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20060270689-A1 | Novel Fused Heterocycles and Uses Thereof | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
| EP-1601673-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | AstraZeneca AB (SE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078758-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | RB1, CDK19, PRMT9 | KIF11 1978/4885SMN1; SMN2 2764/4885MAPT 4736/4885 |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | RB1, CDK19, PRMT9 | KIF11 1978/4885SMN1; SMN2 2764/4885MAPT 4736/4885 |
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | KIF11 4462/4885SMN1; SMN2 3546/4885MAPT 3367/4885 |
| US-20060270689-A1 | Novel Fused Heterocycles and Uses Thereof | BRCA1, CYP1B1, CCNI | KIF11 3559/4885SMN1; SMN2 2206/4885MAPT 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.